Latest Clinical Trial Updates for ATTR-CM and AL-CM
ATTR-CM poses a significant clinical challenge, affecting a growing number of individuals worldwide. In this broadcast entitled 'Latest Clinical Trial Updates for ATTR-CM and AL-CM', Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) with Dr Heather Landau (Memorial Sloan Kettering Cancer Center, US), Prof Dan Lenihan (Saint Francis Healthcare System, US) and Prof Joe Carver (University of Pennsylvania, US) will navigate through the intricacies of ATTR-CM, providing a comprehensive overview of ongoing clinical trials, emerging therapeutic modalities, and the evolving landscape of patient management.
Join us as the faculty explore the latest findings, discuss potential implications for clinical practice, and address the challenges and opportunities within the ATTR-CM research.
The partnership combines Radcliffe’s rapidly growing global community and expertise in delivering the most innovative virtual events, with the knowledge and experience of IC-OS’s members, to curate broadcasts that challenge current practice and have real-world patient benefits.
This broadcast is for cardiologists, haematologists, oncologists, nurse practitioners, nurses and pharmacists.
The International Cardio-Oncology Society is a committed group of professionals throughout the world who are striving to protect the cardiovascular health of all patients who are undergoing cancer therapy. By optimising the cardiac status of patients with cancer before, during and after their treatment, IC-OS is collectively improving the overall outcomes including survival and quality of life. IC-OS aims to provide the latest scientific and clinical education and research for anyone treating patients with cancer in the hopes of enhancing cardiovascular protection.
This is an independent activity run by the International Cardio-oncology Society (ICOS) and co-produced in collaboration with Radcliffe Cardiology. IC-OS has been provided support to deliver this webinar series by AstraZeneca, BMS/Pfizer Alliance and Sumitomo Pharma through an unrestricted educational grant to cover organisational costs and has had no input into the agenda or content of this educational activity. Radcliffe Cardiology has received no industry funding.
Heather J Landau
This broadcast is supported by
Dr Michelle Kittleson is Professor of Medicine at Cedars-Sinai and Director of Education in Heart Failure and Transplantation at the Smidt Heart Institute. She graduated from Harvard College and received her medical degree from Yale University. She completed residency training at Brigham and Women's Hospital and cardiology fellowship at Johns Hopkins, where she also received a PhD in Clinical Investigation.
Dr Kittleson is Interim Editor-in-Chief of the Journal of Heart and Lung Transplantation, on writing committees for the ACC/AHA Hypertrophic Cardiomyopathy Guidelines and the ACC/AHA/HFSA HF Guidelines, Co Editor-in-Chief for the ACC Heart Failure Self-Assessment Program, and on the Board of Directors for the Heart Failure Society of America. Her essays have appeared in the New England Journal of Medicine, Annals of Internal Medicine, and JAMA Cardiology and poems in JAMA and Annals of Internal Medicine. Her book, Mastering the Art of Patient Care, is available from Springer publishing.
Prof Daniel Lenihan is a cardio-oncologist specialising in cardiology, heart disease and advanced heart failure, at Saint Francis Healthcare System, Cape Girardeau, US.
He is a co-Founder and Board Member of the International Cardio-Oncology Society (ICOS), which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.
He is actively involved in patient care as the Director of the Cardio-Oncology Programme, Cardiac Rehabilitation, and the Heart Failure clinic at Saint Francis Healthcare System.
Prof Joe Carver is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, Philadelphia, US. He is the Chief of Staff at the Abramson Cancer Center.
He is the Director of the Thalheimer Cardio-oncology Center at the Abramson Cancer Center and his clinical practice is in the subspecialty of cardio-oncology.
Heather J Landau
Dr Heather J Landau, MD is an Associate Attending Physician on the Adult Bone Marrow Transplant, Cellular Therapy and Multiple Myeloma services at Memorial Sloan Kettering (MSK) Cancer Center, New York, US and is the Director of the Amyloid Program. She is also an Associate Professor of Clinical Medicine at Weill Cornell Medical College. She received her MD from Upstate Medical University and after an Internal Medicine Residency at the University of Colorado, she pursued her Hematology and Oncology Fellowship at MSK where she remains on faculty. Her career has focused on improving outcomes for patients with plasma cell disorders including both Multiple Myeloma (MM) and Light Chain (AL) Amyloidosis.
Dr Landau has led several investigator-initiated trials focused on increasing access to novel, effective therapies and has developed innovative ways to deliver high-dose therapy and stem cell transplant. Translational efforts have focused on genomic and immune profiling of pathologic plasma cells in MM and AL amyloidosis and developing a novel blood-based technique to track minimal residual disease. She is currently a co-chair for the Center for International Blood & Marrow Transplant Research (CIBMTR) Working Committee for Plasma Cell Disorders, member of the International Kidney Monoclonal Gammopathy consortium where she leads the Renal Transplantation Working Group. She is the recipient of an American Society of Hematology Bridge Grant for her work on minimal residual disease and along with Dr Liu is a co-PI on J&J’s Improving Detection of AL Amyloidosis QuickFire Challenge Grant.